Effect of Atorvastatin, Vitamin E and C on Nonalcoholic Fatty Liver Disease: Is the Combination Required?

被引：33
作者：
Arendt, Bianca M. [1 ]
Allard, Johane P. [1 ]
机构：
[1] Univ Hlth Network, Dept Med, Toronto, ON, Canada
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2011年 / 106卷 / 01期
关键词：
STEATOHEPATITIS; PLACEBO; THERAPY;
D O I：
10.1038/ajg.2010.310
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Nonalcoholic fatty liver disease is associated with the metabolic syndrome. The current standard of care, healthy diet and weight loss, has limited effect. The benefits of pharmacological treatments are unclear due to the difficulty of using liver histology as the main outcome in large randomized controlled trials (RCTs). In this issue, an RCT (1) with atorvastatin and antioxidants (vitamins E+C) vs. placebo shows improvement in liver steatosis based on computed tomography scans. The questions are (1) is this beneficial effect due to the combined treatment or the effect of an individual compound; (2) does this intervention improve nonalcoholic steatohepatitis.
引用
收藏
页码：78 / 80
页数：3
相关论文
共 25 条
  • [1] Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients
    Antonopoulos, S
    Mikros, S
    Mylonopoulou, M
    Kokkoris, S
    Giannoulis, G
    [J]. ATHEROSCLEROSIS, 2006, 184 (01) : 233 - 234
  • [2] Rationale and design of the St. Francis Heart Study: A randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification
    Arad, Y
    Newstein, D
    Roth, M
    Guerci, AD
    [J]. CONTROLLED CLINICAL TRIALS, 2001, 22 (05): : 553 - 572
  • [3] Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
    Browning, JD
    Szczepaniak, LS
    Dobbins, R
    Nuremberg, P
    Horton, JD
    Cohen, JC
    Grundy, SM
    Hobbs, HH
    [J]. HEPATOLOGY, 2004, 40 (06) : 1387 - 1395
  • [4] Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?
    Dietrich, M.
    Jacques, P. F.
    Pencina, M. J.
    Lanier, K.
    Keyes, M. J.
    Kaur, G.
    Wolf, P. A.
    D'Agostino, R. B.
    Vasan, R. S.
    [J]. ATHEROSCLEROSIS, 2009, 205 (02) : 549 - 553
  • [5] Pathogenesis of non-alcoholic fatty liver disease
    Dowman, J. K.
    Tomlinson, J. W.
    Newsome, P. N.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2010, 103 (02) : 71 - 83
  • [6] Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study
    Drakoulis, CK
    Parasi, AS
    [J]. ATHEROSCLEROSIS, 2004, 174 (01) : 193 - 196
  • [7] Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial
    Foster, Temitope
    Budoff, Matthew J.
    Saab, Sammy
    Ahmadi, Naser
    Gordon, Craig
    Guerci, Alan D.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (01) : 71 - 77
  • [8] A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients
    Gomez-Dominguez, E.
    Gisbert, J. . P.
    Moreno-Monteagudo, J. A.
    Garcia-Buey, L.
    Moreno-Otero, R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (11) : 1643 - 1647
  • [9] Hatzitolios Apostolos, 2004, Indian J Gastroenterol, V23, P131
  • [10] Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia
    Hyogo, Hideyuki
    Tazuma, Susumu
    Arihiro, Koji
    Iwamoto, Keiko
    Nabeshima, Yoshitaka
    Inoue, Motoki
    Ishitobi, Tomokazu
    Nonaka, Michihiro
    Chayama, Kazuaki
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2008, 57 (12): : 1711 - 1718
123